Country of origin: Hungary, Pierre Fabre Medicine Production France, Terabelle Pharma Belgium, Thyssen Laboratories Belgium
Pharm-Group: Alkaloids and other cytostatic agents of plant origin
Manufacturers: Gedeon Richter A.O. (Hungary), Pierre Fabre Medicine Production (France), Terabelle Pharma (Belgium), Thyssen Laboratories (Belgium)
International name: Vincristine
Synonyms: Vero-Vincristine, Vincristine sulfate, Vincristine-LENS, Vincristine-Richter, Vincristine-Teva, Vincristine sulfate, Oncocristine, Cytocristin, Cytomide
Dosage forms: lyophilized powder for the preparation of injection solution 0.5 mg, solution for injection 1 mg/ml, solution for injection 5 mg, lyophilized powder for the preparation of injection solution 1 mg
Composition: Active substance - Vincristine.
Indications for use: Acute lymphoblastic leukemia, lymphogranulomatosis, non-Hodgkin's lymphomas, rhabdomyosarcoma, bone and soft tissue sarcomas, Ewing's sarcoma, neuroblastoma, Wilms tumor, breast cancer, epithelioma, small cell lung cancer, idiopathic thrombocytopenic purpura, solid tumors in adults (as a component chemotherapy).
Contraindications: Hypersensitivity, bone marrow hypoplasia, diseases of the nervous system, pregnancy, breastfeeding.
Side effects: Abdominal pain, nausea, paralytic ileus, neuropathy, loss of some types of sensitivity and tendon reflexes, severe paresthesia, jaw pain, ataxia, decreased muscle strength, cranial nerve damage, alopecia, moderate leukopenia, thrombocytopenia, disorder ADH secretion, polyuria, dysuria, fever.
Interaction: Weakens the effect of anti-gout drugs. Increases the neurotoxicity of other drugs. The likelihood of developing respiratory depression and bronchospasm increases against the background of mitomycin C. Reduces the elimination of L-asparaginase.
Overdose: Symptoms - increased severity of side effects. Treatment: prevention of the syndrome of impaired ADH secretion (liquid restriction, prescription of a diuretic), administration of phenobarbital (to prevent seizures) and other means of symptomatic therapy, lavage.
Special instructions: To prevent acute urate nephropathy, it is necessary to regularly monitor the level of uric acid in plasma and ensure adequate diuresis. During treatment, the composition of peripheral blood should be monitored.
Literature: Encyclopedia of Medicines, 2003.